In Vitro Pharmacodynamic Effects of Cangrelor in Ticagrelor Treated Patients

Completed · Not applicable

Conditions studied: Coronary Artery Disease

In brief

Cangrelor is a potent intravenous P2Y12 receptor inhibitor with rapid onset and offset of action associated with a greater reduction in ischemic events, including stent thrombosis, in patients undergoing stent procedures who have not been pretreated with clopidogrel. In vitro investigations have shown cangrelor to be associated with more rapid, potent, and consistent platelet inhibition in patients on maintenance prasugrel therapy exposed to a re-loading dose of prasugrel. However, if cangrelor exerts similar effects in ticagrelor treated patients remain unknown. The aim of the present study is to evaluate the effects on platelet function achieved after in vitro incubation with cangrelor in patients on ticagrelor maintenance dose who receive a loading dose of ticagrelor.

Key facts

Study ID: NCT02081443
Run by: University of Florida
People needed: 60
Starts: 2014-04-01
Expected to finish: 2015-10-01
Last updated by the study team: 2017-04-04

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patients with angiographically documented coronary artery disease.
Age between 18 to 80 years
On treatment per standard of care with ticagrelor 90mg/b.i.d. and aspirin <100mg/day for at least 14 days.

You may not qualify if…

History of intracranial bleeding
Known severe hepatic dysfunction
Known hypersensitivy
Active bleeding or propensity to bleed
Platelet count <80x106/mL
Hemodynamic instability
Serum creatinine <30 mL/min
Use of oral anticoagulants (Vitamin K antagonist, dabigatran, rivaroxaban, apixaban)
Recent (<14 days) antiplatelet treatment with a glycoprotein IIb/IIIa inhibitor
Blood dyscrasia
Patients with sick sinus syndrome (SSS) or II or III degree AV block without pacemaker
Drugs interfering CYP3A4 metabolism (to avoid interaction with Ticagrelor): Ketoconazole, itraconazole, voriconazole, clarithromicin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir and telithromizycin
Hemoglobin < 10g/dL
Pregnant females [women of childbearing age must use reliable birth control (i.e. oral contraceptives) while participating in the study].

Where it is running

Dominick Angiolillo — Jacksonville, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.